Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMPI-3 - A Randomized Controlled Trial of High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

NCT04521803 is registered in ClinicalTrials.gov with University of Cape Town as lead sponsor.

NCT NCT04521803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMPI-3 - A Randomized Controlled Trial of High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
Lead sponsor
University of Cape Town
Phase
Phase 2
Overall status
Completed
Start date
January 10, 2022
Completion date
June 10, 2026
Enrollment
52 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv status, tuberculous pericarditis